Product
Endocrine therapy
Aliases
anastrazole, exemestane, fulvestrant, letrozole
17 clinical trials
20 indications
Indication
Breast CancerIndication
Breast NeoplasmsIndication
Breast Cancer MetastaticIndication
HR+ HER2- MenIndication
Advanced Breast CancerIndication
Early Breast CancerIndication
Breast Cancer (HER2-positive)Indication
TherapyIndication
Low Heart RateIndication
Brain MetastasesIndication
Metastatic Breast CancerIndication
Hormone Receptor Positive TumorIndication
HR+/HER2- Advanced Breast CancerIndication
Targeted TherapyIndication
ultrasonographyIndication
ElastographyIndication
DiseaseIndication
RadiomicsClinical trial
A Randomized, Double-Blind, Phase III Study of Pembrolizumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (KEYNOTE-756)Status: Active (not recruiting), Estimated PCD: 2031-01-24
Clinical trial
A Phase 1b Study of Abemaciclib in Combination With Therapies for Patients With Metastatic Breast CancerStatus: Active (not recruiting), Estimated PCD: 2021-03-15
Clinical trial
Phase 2 Study of MCLA-128-based Combinations in Metastatic Breast Cancer (MBC): MCLA-128/Trastuzumab/Chemotherapy in HER2-positive MBC and MCLA-128/Endocrine Therapy in Estrogen Receptor Positive and Low HER2 Expression MBCStatus: Completed, Estimated PCD: 2022-10-26
Clinical trial
A Phase 2 Study of Alisertib in Combination With Endocrine Therapy in Patients With HR+, HER2-negative Recurrent or Metastatic Breast CancerStatus: Not yet recruiting, Estimated PCD: 2027-06-30
Clinical trial
Treatment of Canadian Men and Pre/Postmenopausal Women With ER+ Advanced Breast Cancer in the Real-World Setting With Hormone Therapy ± Targeted TherapyStatus: Completed, Estimated PCD: 2022-12-01
Clinical trial
PreOperative Endocrine Therapy for Individualised Care With AbemaciclibStatus: Recruiting, Estimated PCD: 2030-09-30
Clinical trial
Efficacy and Safety of Dalpiciclib With Endocrine Therapy as Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative Early Breast CancerStatus: Recruiting, Estimated PCD: 2027-06-01
Clinical trial
A Randomized, Open-label, Phase II Trial Comparing Neoadjuvant Endocrine Therapy in Combination With Trastuzumab, Pertuzumab +/- the PI3K Inhibitor Inavolisib in Patients With HER2-positive, HR-positive, PIK3CA Mutant Early Breast Cancer-GeparPiPPaStatus: Recruiting, Estimated PCD: 2026-10-01
Clinical trial
Combination Followed by Maintenance Chemotherapy Versus CDK4/6 Inhibitor Combined With Endocrine Therapy for HR Low/HER2-negative Advanced Breast Cancer: a Prospective, Randomized, Open-label Phase Ⅱ Clinical TrialStatus: Not yet recruiting, Estimated PCD: 2025-12-20
Clinical trial
Phase I/II Study of Stereotactic Radiation and Abemaciclib in the Management of Hormone Receptor Positive HER2 Negative Breast Cancer Brain MetastasesStatus: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Pragmatic Randomised, Trial Evaluating an Endocrine Therapy Dose-frequency Escalation Strategy and Its Effects on Tolerability and Compliance (REaCT-TEMPO)Status: Recruiting, Estimated PCD: 2025-07-01
Clinical trial
A Pilot Study of IMMUNe mOdulation in Early Stage Estrogen Receptor Positive Breast Cancer Treated With neoADjuvant Avelumab, Palbociclib, and Endocrine Therapy: The ImmunoADAPT StudyStatus: Active (not recruiting), Estimated PCD: 2024-07-31
Clinical trial
International,Multicenter,Randomized,Open-label, Phase II to Evaluate the Efficacy and Safety of Continuation of Palbociclib+2nd Line Endocrine Therapy in HR+/HER2- ABC Patients Who Had Clinical Benefit During 1st Line Palbociclib.Status: Completed, Estimated PCD: 2022-11-30
Clinical trial
A Prospective Cohort, Open, Phase II Clinical Study of Chidamide/Everolimus Combined With Endocrine Therapy for PIK3CA Wild-type/Mutant Hormone Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative Advanced Breast CancerStatus: Recruiting, Estimated PCD: 2026-07-15
Clinical trial
Application of Radiomics in Correlation Between Ultrasound Characteristics and Pathological Prognostic Factors in Breast CancerStatus: Recruiting, Estimated PCD: 2023-12-01
Clinical trial
A Phase III Randomized, Double-Blind, Neoadjuvant Study of Hormonal Therapy Plus Palbociclib Versus Hormonal Therapy Plus Placebo in Women With Operable, Hormone Sensitive and HER2-Negative Primary Breast CancerStatus: Completed, Estimated PCD: 2021-12-23
Clinical trial
ECLECTIC: EstroTEP and Circulating Biomarkers to Determine the Optimal Second Line Therapy for ER-positive HER2-negative Metastatic Breast Cancer PatientsStatus: Recruiting, Estimated PCD: 2028-08-15